par Racu, Marie-Lucie 
;Bernardi, Dana ;Chaouche, Aniss;Zindy, Egor ;Navez, Julie ;Loi, Patrizia ;Maris, Calliope ;Closset, Jean ;Van Laethem, Jean-Luc ;Decaestecker, Christine ;Salmon, Isabelle ;D'Haene, Nicky
Référence Cancers (Basel), 15, 15
Publication Publié, 2023-07
;Bernardi, Dana ;Chaouche, Aniss;Zindy, Egor ;Navez, Julie ;Loi, Patrizia ;Maris, Calliope ;Closset, Jean ;Van Laethem, Jean-Luc ;Decaestecker, Christine ;Salmon, Isabelle ;D'Haene, Nicky Référence Cancers (Basel), 15, 15
Publication Publié, 2023-07
Article révisé par les pairs
| Résumé : | SMAD4 is inactivated in 50-55% of pancreatic ductal adenocarcinomas (PDACs). SMAD4 loss of expression has been described as a negative prognostic factor in PDAC associated with an increased rate of metastasis and resistance to therapy. However, the impact of SMAD4 inactivation in patients receiving neoadjuvant therapy (NAT) is not well characterized. The aim of our study was to investigate whether SMAD4 status is a prognostic and predictive factor in patients receiving NAT. |
